Iovance Biotherapeutics
IOVA
200 hedge funds and large institutions have $3.44B invested in Iovance Biotherapeutics in 2019 Q4 according to their latest regulatory filings, with 45 funds opening new positions, 75 increasing their positions, 60 reducing their positions, and 13 closing their positions.
573% more call options, than puts
Call options by funds: $62.1M | Put options by funds: $9.22M
246% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 13
53% more capital invested
Capital invested by funds: $2.25B → $3.44B (+$1.19B)
25% more funds holding in top 10
Funds holding in top 10: 8 → 10 (+2)
25% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 60
16% more funds holding
Funds holding: 173 → 200 (+27)
1.31% less ownership
Funds ownership: 99.69% → 98.38% (-1.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$46M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$28.5M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$16M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$9.84M |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$7.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$40.4M |
| 2 |
PA
Perceptive Advisors
New York
|
-$36.4M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$24.8M |
| 4 |
BC
Broadfin Capital
New York
|
-$13.6M |
| 5 |
State Street
Boston,
Massachusetts
|
-$9.87M |
IOVA Hedge Fund Activity: Q4 2019 in Review
200 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q4 2019, worth a combined $3.44B — up 53% from $2.25B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new IOVA positions and 13 closed out — a net gain of 32 holders — while 75 added to existing stakes and 60 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $46M. The largest seller was Avoro Capital Advisors, cutting an estimated $40.4M.
- 200 institutional investors held Iovance Biotherapeutics (IOVA) as of Q4 2019, up from 173 in Q3 2019.
- Funds reported $3.44B of Iovance Biotherapeutics stock for Q4 2019, up 53% quarter-over-quarter.
- 45 funds opened new Iovance Biotherapeutics positions in Q4 2019 and 13 closed out, a net change of +32 holders.
- The largest Iovance Biotherapeutics buyer in Q4 2019 was Point72 Asset Management, an estimated $46M added.
- The largest Iovance Biotherapeutics seller in Q4 2019 was Avoro Capital Advisors, an estimated $40.4M sold.
Based on aggregated 13F filings for Q4 2019.